logo
ProjectEnded

Additive Printing for Cell-Based Analysis

Ended · United Kingdom

Source: EU Funding & Tenders Portal

The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists. The technical solution is to assemble cell models by additive manufacturing; to control the resident cells’ locations within these 3D models; to supply the models to custo

Status
Closed
Sector
Hospital, Manufacturing (Industrial), Commercial
Location
United Kingdom
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Additive Printing for Cell-Based Analysis

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Additive Printing for Cell-Based Analysis” is an infrastructure initiative in the Hospital sector, located in United Kingdom. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists. The technical solution is to assemble cell models by additive manufacturing; to control the resident cells’ locations within these 3D models; to supply the models to customers as pre-assembled, frozen products. The result shall be an analytical tool which, unlike current practice, does not compromise analytical output for convenience, but combines high predictive value and low cost with exceptional user-friendliness. The solution is unique, proprietary and highly positive-disruptive in its industrial sector. Its achievement will be measurable in this Project as an exemplifying, printed hepatotoxicity assay with wide application in drug discovery and biosafety testing. An SME Instrument Phase 1 Project advanced the core printing technology delivering this solution to TRL7, and developed a business plan for its exploitation. That business plan confirmed the wide, cross-industry application of cell-based analysis, from preclinical drug discovery through natural products/food to medical devices and nanosafety, and mapped the advantages of additively-manufactured products onto demonstrable industry trends and customer needs. The business plan and its underpinning technology are founded in the applicant’s long-term strategic goals, evidenced by profitable business in the target market from proprietary cell-based services, and by ancillary technology developments, also to TRL7 and supported by UK national funding, which create unique competitive advantage. The outcome of this Phase 2 Project will be a mature cell-based manufacturing technology, its demonstrable application in a commercial environment, and the assembly of a corporate infrastructure ready to take the Project’s manufacturing solution into a well-scoped and lucrative marketplace.

Location

Country

United Kingdom (UK)

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Manufacturing (Industrial), Commercial

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project